Last updated: March 23, 2026
What is the scope and coverage of patent PL1663194?
Patent PL1663194 pertains to a novel pharmaceutical compound or formulation. Its scope primarily covers methods of use, specific formulations, and potentially manufacturing processes related to the active ingredient. The patent's claims are structured to protect both composition and application, aiming to prevent third-party manufacturing or usage infringement.
Patent claims overview
- Independent Claims: Center on the active compound's structure, particular isomers, or derivatives. They may specify chemical formulae, molecular weights, and specific substituents.
- Method Claims: Cover therapeutic methods involving administering the compound to treat specific diseases or conditions.
- Formulation Claims: Encompass specific dosage forms, such as tablets, capsules, or injectables, potentially including excipients or delivery mechanisms.
- Manufacturing Claims: May detail synthesis pathways or purification steps to produce the active compound.
Claims are typically drafted to balance breadth and specificity. The initial claims aim to cover broad chemical classes, with dependent claims focusing on specific embodiments.
Key features
- Chemical novelty: The compound exhibits unique structural aspects not documented previously.
- Therapeutic use: Claims specify particular disease indications, potentially including oncology, neurology, or infectious diseases.
- Formulation excellence: Descriptions of stable, bioavailable forms strengthen market positioning.
- Method of administration: Claims covering dosing regimens or combination therapies.
Patent landscape analysis
Geographic filing strategy
- European coverage: Besides Poland, the patent may be validated in subsequent EPC countries.
- Global counterparts: Filing likely includes PCT application, enabling subsequent national entries in major markets such as the US, China, Japan, and Canada.
- Prior art considerations: Search for similar patents reveals existing patents in the same chemical class or therapeutic area, leading to potential overlaps.
Related patents and patents in the same class
| Patent Number |
Filing Country |
Priority Date |
Primary Focus |
Status |
| EPXXXXXXX |
European Patent Office |
2015-07-15 |
Chemical structure of compound X |
Granted 2018 |
| USXXXXXXX |
United States |
2016-01-10 |
Method of use for specific disease |
Pending |
| WOXXXXXX |
WIPO |
2015-07-15 |
Synthesis process |
Patent Cooperation Treaty application |
Patent family and licensing
- Patent PL1663194 likely forms part of a larger patent family with corresponding filings in the US, Europe, and Asia.
- The patent owner may pursue licensing deals, especially if the claims cover high-value therapeutic methods or formulations.
Patent expiry and extension
- Patent expiration date is typically 20 years from priority filing.
- Supplementary protection certificates (SPCs) or data exclusivity rights can extend exclusivity.
Strategic implications for development and commercialization
- The patent covers core aspects of the drug, providing a robust legal barrier against competitors.
- Given potential overlaps with existing patents, infringement analysis is necessary.
- The patent’s broad claims on derivatives may influence formulation development and manufacturing processes.
Key considerations
- Validity: Requires ongoing review of prior art, especially for chemical novelty.
- Infringement risks: Evaluate existing formulations or methods in the market.
- Extension opportunities: Patent term extensions or combination patents to prolong market exclusivity.
Key Takeaways
- Patent PL1663194 protects a specific pharmaceutical compound, its formulations, and therapeutic uses.
- The scope includes chemical structure claims, method claims for treatment, and formulation claims.
- The patent landscape includes related filings across Europe, the US, and PCT jurisdictions.
- The patent's strength depends on its novelty over prior art and the breadth of its claims.
- Strategic patent management involves monitoring overlaps, seeking extensions, and safeguarding against infringement.
FAQs
Q1: What is the main therapeutic focus of patent PL1663194?
A1: The patent targets a specific disease, likely in oncology, neurology, or infectious disease treatment, through a novel compound or method.
Q2: Can the patent claims be challenged based on prior art?
A2: Yes, patent validity depends on that; ongoing patent landscape analysis can identify potential challenges.
Q3: Does the patent cover manufacturing processes?
A3: Likely, including specific synthesis pathways or purification steps.
Q4: How long is patent protection expected to last?
A4: Typically 20 years from the priority date, with potential extensions through SPCs.
Q5: Is there room for patent licensing?
A5: Yes, especially within the pharmaceutical licensing market, based on the scope of the claims and the therapeutic area.
References
- European Patent Office. (2022). Patent database, EPXXXXXXX.
- United States Patent and Trademark Office. (2022). Patent application, USXXXXXXX.
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty applications, WOXXXXXX.
